0001209191-20-038339.txt : 20200622
0001209191-20-038339.hdr.sgml : 20200622
20200622211756
ACCESSION NUMBER: 0001209191-20-038339
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200622
FILED AS OF DATE: 20200622
DATE AS OF CHANGE: 20200622
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Howton David T
CENTRAL INDEX KEY: 0001529297
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 20980146
MAIL ADDRESS:
STREET 1: VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930797222
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-274-4000
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-06-22
0
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001529297
Howton David T
215 FIRST STREET, SUITE 415
CAMBRIDGE
MA
02142
0
1
0
0
EVP, General Counsel
Common Stock
2020-06-22
4
M
0
1280
13.71
A
33151
D
Common Stock
2020-06-22
4
M
0
1858
13.71
A
35009
D
Common Stock
2020-06-22
4
M
0
56984
23.85
A
91993
D
Common Stock
2020-06-22
4
M
0
45000
29.03
A
136993
D
Common Stock
2020-06-22
4
S
0
6009
168.61
D
130984
D
Common Stock
2020-06-22
4
S
0
8086
169.56
D
122898
D
Common Stock
2020-06-22
4
S
0
35757
170.59
D
87141
D
Common Stock
2020-06-22
4
S
0
55270
171.50
D
31871
D
Stock option (right to buy)
13.71
2020-06-22
4
M
0
1280
0.00
D
2017-02-28
2026-02-28
Common Stock
1280
0
D
Stock option (right to buy)
13.71
2020-06-22
4
M
0
1858
0.00
D
2017-02-28
2026-02-28
Common Stock
1858
0
D
Stock option (right to buy)
23.85
2020-06-22
4
M
0
56984
0.00
D
2013-11-05
2022-11-05
Common Stock
56984
0
D
Stock option (right to buy)
29.03
2020-06-22
4
M
0
45000
0.00
D
2015-02-28
2024-02-28
Common Stock
45000
7708
D
This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.
The shares were sold in transactions at prices ranging from $168.04 to $169.0399, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
The shares were sold in transactions at prices ranging from $169.09 to $170.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
The shares were sold in transactions at prices ranging from $170.09 to $171.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
The shares were sold in transactions at prices ranging from $171.09 to $172.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
/s/ David Tyronne Howton
2020-06-22